恶性肿瘤患者化疗后骨髓抑制期静脉通路安全管理

Safe management of venous access in malignant tumor patients with bone marrow suppression after chemotherapy

目的探讨静脉通路安全管理在恶性肿瘤患者化疗后骨髓抑制期对治疗过程中降低静脉导管相关并发症的效果。方法选取2014年1月至2016年12月在我科实施静脉通路安全管理的患者共1 784例,比较患者3年内导管静脉炎及导管穿刺点出血的发生率。结果 1 784例患者实施静脉通路安全管理后,静脉炎与静脉穿刺点出血发生率显著降低,静脉炎发生率由7.7%降至1.6%,差异具有统计学意义(P<0.05);静脉穿刺点出血发生率由6.0%降至1.1%,差异具有统计学意义(P<0.05)。结论对恶性肿瘤化疗后骨髓抑制期患者进行静脉通路安全管理,大大降低了患者骨髓抑制期管路并发症的发生率,值得临床推广使用。

Objective To explore the effect of venous access safety management on decreasing the incidence of venous catheter-related complications during the course of bone marrow suppression in patients with malignant tumor after chemotherapy. Methods A total of 1 784 patients underwent intravenous access safety management in our department from January 2014 to December 2016 were selected. The incidences of catheter phlebitis and catheter puncture bleeding in patients within 3 years were compared. Results After intravenous access safety management, the incidences of catheter phlebitis and catheter puncture bleeding significantly decreased, the incidence of catheter phlebitis reduced from 7.7% to1.6%, the difference was statistically significant（P〈0.05）, the incidence of catheter puncture bleeding reduced from 6.0%to 1.1%, the difference was statistically significant（P〈0.05）. Conclusion Venous access safety management in patients with malignant tumor after chemotherapy can reduce the incidence of venous catheter-related complications during the course of bone marrow suppression, which is worthy of promotion and application in clinic.